Aerie Pharmaceuticals (NSDQ:AERI) said today that it expanded its drug-delivery R&D deal with DSM Biomedical.
The two companies first joined forces in July last year to evaluate the sustained delivery of certain Aerie drugs using DSM’s polymer technology. Initially, the group was focused on developing drug-delivery tech for people with wet age-related macular degeneration and diabetic macular edema.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie expands drug-delivery tech deal with DSM Biomedical appeared first on MassDevice.